Introduction
There is a widely acknowledged need for novel biomarkers of tuberculosis (TB), for all levels of TB diagnosis, treatment, and prevention. [1] [2] [3] Much effort in this direction has been devoted to host biomarkers, because progression towards clinical disease can be detected by specific changes that are evoked by the pathological processes in the host organism. In TB, this is a particular advantage, as the diagnosis of direct symptoms of TB (e.g., by [ 1 0 _ T D $ D I F F ] auscultation or chest X-ray (CXR), through detection of the causative agent, acidfast bacteria in sputum by microscopy, or positive bacterial cultures)[ 1 1 _ T D $ D I F F ] may sometimes be problematic. Sputum samples are difficult to obtain from neonates, who moreover frequently suffer from extrapulmonary TB. However, there are further reasons to focus on the host response. The onset of active TB disease is frequently delayed for years, and the time span between the first TB symptoms and diagnosis has been estimated to range from 5 days to as long as 162 days. 4 [ 1 _ T D $ D I F F ] Thus, TB may exist without apparent symptoms, although the molecular processes underlying TB pathology have already commenced. Likewise, TB may persist in a subclinical stage after drug treatment and may later relapse. Positron emission computed tomography (PET/CT) has revealed hallmarks of active TB in patients who have been treated successfully. 5 Host biomarkers may provide a sensitive and specific approach to detect subclinical manifestations of clinical or subclinical TB. The early detection of TB is another important area for biomarker research. Of two billion Mycobacterium tuberculosisinfected individuals, most remain healthy but infected (latent TB infection, LTBI) and only a fraction of 5-7% will develop clinical TB during their lifetime. Although M. tuberculosis infection can be determined reliably by interferon gamma release assay (IGRA), this test cannot be used to diagnose or determine the prognosis of active TB. 6 Thus, the identification of biomarkers of TB risk and early stage of progression to active TB would allow screening for individuals at risk. This would allow preventive drug therapy, and also interruption of transmission, with a marked influence on treatment success. Practically, the treatment outcome cannot be assessed in a point-of-care setting. Although PET/CT has predictive value for the treatment outcome, 7 [ 2 _ T D $ D I F F ] simpler and more accessible tests have thus far failed. For example, although CXR allows a reliable diagnosis of TB, it has limited predictive value for the treatment outcome. 8 Early and personalized treatment adjustment, as well as prediction of the treatment outcome in new drug trials is a major concern in the face of increasing incidences of drug-resistant TB.
Computational approaches to high-throughput biomarkers
High-throughput techniques such as transcriptomics allow the inspection of tens of thousands of variables (such as gene expression, protein or metabolite levels) in one step (A glossary of the terms used in this article is given in Table 1 ). However, the large number of variables (compared to the number of samples analysed) is a two-edged sword. The obvious advantage of such an approach is the comparatively unbiased acquisition of a large number of potential candidates. On the other hand, if the number of variables is much larger than the number of samples utilized, sophisticated and careful statistical analyses are necessary. Most importantly, the statistical power for detecting a single or a few suitable biomarkers amongst the thousands of variables analysed decreases profoundly, thus correct signals are often hidden in a deluge of false-positives. Moreover, given that the number of functionally characterized protein-coding genes remains insufficient, and only a few microRNAs have been functionally characterized, the interpretation of results may pose an additional obstacle. include both established methods (such as linear discrimination analysis, 10 k-nearest neighbour algorithm, 11 and random forests 12, 13 ) and novel, unique approaches. Zak et al. 14 constructed a new classification method by combining k-top-scoring pairs 15 with support vector machines (SVMs), taking advantage of relatively simple interpretability of the k-top-scoring pairs approach with the flexibility of SVMs. Kaforou et al. defined a new metrics termed the 'disease risk score' (DSR), defined as the sum of signed absolute intensities of discriminatory biomarkers, combined with a TB/no TB threshold. 16 Despite the computational simplicity of DSR, it was shown to perform well in discriminating TB patients both from healthy individuals and from patients suffering from other diseases. A disease signature is only superficially a compilation of variables (e.g., genes) that differ between two conditions. Firstly, as a minimum these variables are linked to particular values (e.g., gene expression in healthy individuals and in TB patients, as in the k-nearest neighbour algorithm) or more complex structures (e.g., decision trees). Secondly, most machine learning algorithms provide a score, which subsequently is compared to an arbitrarily chosen threshold. This latter step, however, depends on a given context, because modifying the threshold optimizes either specificity or sensitivity. As a solution, results of such biomarker analyses are frequently shown as so-called receiver operating characteristic (ROC) curves-all possible sensitivity/specificity combinations for a given signature ( Figure 1A ).
The interpretation of signatures is increasingly confounded by the size and complexity of the model. While biological functions to which a four-gene signature is related may be glimpsed with relative ease, it is much harder to gain an overview in more complex cases. However, machine learning algorithms often allow the calculation of a 'variable importance' (VI) measure. VI can be used to rank genes according to their contribution to the model, which in turn can be used by adapting a gene set enrichment analysis framework such as GSEA 21 
shrunken model based on a subset of genes, the subset itself can be tested for enrichment in relevant classes of genes. Note that all statistical approaches are based on assumptions, which incompletely fit the biological reality. Moreover, the large number of variables tested in a high-throughput setting increases the risk of false-positives, even when strictly adhering to standards in statistical methodology, e.g. by using a suitable method for family-wise error correction. It has been estimated that at p < 0.05, as many as 30% of the rejected hypotheses may be falsepositives, 23 irrespective of using a correction for multiple testing, which may be one of the reasons for the much debated 'reproducibility crisis' in science. The point here is that highthroughput analyses are especially vulnerable to these problems. Three not mutually exclusive approaches are suggested here, which do not require additional statistical assumptions or novel techniques. Firstly, because unblinded studies overestimate the actual observed effect size, 24 [ 1 6 _ T D $ D I F F ] any biomarker study in future should consider separating ('locking') a randomly chosen subset of samples for a blinded, post-hoc validation of the findings, and studies should be evaluated by adherence to this rule. Secondly, an independent analysis by several statisticians (both as study authors and reviewers) would greatly increase confidence in the findings. Thirdly, biomarker studies need to be validated in various settings and cohorts, and using independent experimental approaches. This would facilitate the process of translating the high-throughput to practical clinical applications.
3. High-throughput biomarkers in TB
Transcriptomic profiling
High-throughput-derived transcriptomic biomarkers have been studied for almost a decade in TB, with the first studies appearing in 2007. 2, 10, 25 The broadly studied differences in gene expression between TB patients and healthy (infected or uninfected) controls thus far have been investigated in a total of over a thousand individuals on four continents. Kaforou et al. included over 500 individuals in two cohorts, not only TB patients and healthy controls (both HIV-negative and HIV-positive), but also patients who were suspected of having TB but who had been clinically diagnosed with other diseases. 16 The biomarkers identified include components of the interferon gamma response (such as CD64, identified by Jacobsen et al. 25 ), neutrophil-driven interferon signature, 11, 17, 19 [ 1 7 _ T D $ D I F F ] down-regulation of T-cell-and B-cell-related genes, and others. 26, 27 These initial signatures were defined as sets of differentially regulated genes characteristic of gene expression in the blood of TB patients and involved up to several hundred genes. Despite the universality of qualitative findings, the balance in the extent of regulation found to occur in different areas of the host response may differ between the studies. For example, random forest models based on data derived from Berry et al.
[ 1 8 _ T D $ D I F F ]
show a strong interferon response dominating the signature (in concordance with the main conclusions of the authors), while the data from Kaforou et al. 16 are dominated by changes in expression of T-cell-and B-cellrelated genes (see Figure 1B ). It is difficult to decide by purely computational criteria whether these shifts in the different parts of the immune system may be due to different technical platforms or whether they reflect real biological differences. Meta-analyses combined with a rigorous variable selection process allow the size of transcriptomic biosignatures to be reduced to as few as three or four genes (Maertzdorf et al.; 13 Sweeney et al. 28 [
9 _ T D $ D I F F ] ). In fact, a concise ([ 5 _ T D $ D I F F ] shrunken) four-gene signature
based on comparison between healthy controls and TB patients turned out to be more specific for TB than larger signatures involving 15 or more genes, and even allowed the discrimination between TB and other pulmonary diseases when applied to independent data sets and cohorts. 13 It is possible that a broader signature involves genes that capture the general aspects of TB disease (such as inflammation or other unspecific innate responses) shared with other diseases. Note that these concise transcriptomic signatures are remarkably universal, and the models built can be successfully validated on data sets derived from other cohorts and technical platforms used to obtain the data.
Recently, transcriptomic profiling has been applied in a longitudinal study with the goal of obtaining a predictive signature for active TB disease. Zak and colleagues followed healthy adolescents from South Africa for 2 years, collecting blood samples every 6 months.
14 Out of several thousand study participants, 46 individuals were eventually diagnosed with TB. Transcriptomic profiles were obtained from blood samples of these individuals, collected prior to the time point of TB diagnosis, and were compared to profiles of those individuals who remained healthy throughout the study. Indeed, these profiles (which were all collected from apparently healthy individuals) were able to discriminate between the two groups in the study design, with statistical significance, even though the statistical performance (as it was to be expected) was not comparable to the power of transcriptomic profiles in discriminating between healthy individuals and TB patients. The results of the study have been confirmed using an independent set of samples obtained from another longitudinal cohort collected in the Grand Challenges GC6-74 effort.
[ 2 0 _ T D $ D I F F ]
There were two further notable findings in this study. Firstly, the biomarkers identified largely coincided with the biomarkers for clinical TB diagnosis, including CD64 (identified by Jacobsen et al. 25 ) and several interferon inducible genes. 11 In other words, the prognostic or predictive signature of TB obtained overlaps with the diagnostic signature of clinical TB. Secondly, there was a clear time dependence relative to time point of clinical diagnosis: samples obtained within the 12 to 18 months prior to clinical diagnosis produced a predictive signature, but samples obtained earlier did not. These findings suggest that the biomarkers identified do not correspond to a persistent TB risk (or, reciprocally, an inherent protectivity), but more likely are indicative of an incipient, subclinical form of TB. This is in line with recent findings that apparently healthy individuals after successful drug treatment show an ongoing TB process that can be captured with PET.
5
[ ( F i g u r e _ 1 ) T D $ F I G ] This hypothesis will prompt further studies in other or larger cohorts. The elephant in the room when it comes to blood transcriptome studies is the fact that it is generally impossible to reliably distinguish between bona fide gene regulation within a cell and changes or differences in the composition of the cell populations constituting the analysed samples. While differential cell counts sometimes accompany blood transcriptomic data, this is likely insufficient if, for example, the observed effects are due to changes in the migration pattern of T lymphocytes or specific subtypes thereof. Future analyses involving single-cell RNA sequencing (scRNASeq) may shed further light on fine differences in the state of the individual cells and cell compositions of the investigated tissue.
Further high-throughput approaches
Transcriptomic analyses have been followed by large-scale proteomic analyses. De Groote et al. used a highly multiplexed proteomics approach to analyse serum from TB patients before and after treatment and identified a number of potential biomarkers, including C-reactive protein, the metallopeptidase inhibitor TIMP2, thrombospondin 4 (THBS4), and serum amyloid A (SAA), as well as a number of involved pathways, including microbial pattern recognition, coagulation and complement system, as well as, to lesser extent, the interferon gamma pathway. 30 [ 2 Metabolic profiling of serum metabolites by mass spectrometry has demonstrated excellent performance in discriminating TB patients from healthy controls. 12 The analyses revealed changes in lysophosphatidylcholines, amino acids (notably glutamine and glutamate), bile acids, and fibrinopeptides, and the top biomarkers included inosine, cortisol, and kynurenine. Kynurenine is known to correlate with increased expression of indoleamine 2,3-dioxygenase upon contact with M. tuberculosis, while adenosine deaminase, which enzymatically converts adenosine to inosine, has been identified as a potential serum proteomic biomarker for TB. 40 Few investigators have considered epigenetic modifications as potential TB biomarkers. Esterhuyse et al. simultaneously collected DNA methylation data, transcriptomic profiles (including microRNAs), and proteomic profiles from monocytes and neutrophils isolated from TB patients and healthy controls. 39 
[ 2 7 _ T D $ D I F F ]
At the bottom line, these studies demonstrate that the deep impact of TB on the host can reliably be acquired by highthroughput techniques at all levels tested to date. Significant changes in TB can be observed for virtually any tissue and molecule type tested. Universal, but TB-specific patterns emerge, including the interferon response or changes in host metabolism. In spite of this, the data are both too rich and too poor.
Firstly, studies comparing TB to healthy controls are abundant and have generated a diverse landscape of data sets. Meta-analyses (such as the one performed on transcriptomic data by Joosten et al. 26 and that by Sweeney et al. 28 [ 1 9 _ T D $ D I F F ] ) are now a key task for computational analyses. Unfortunately, while primary transcriptomic readouts (i.e., signal intensities for microarrays or read counts for RNASeq) are usually readily available from the GEO database, other types of data are less frequently disclosed upon publication.
On the other hand, most of the aforementioned study designs have primarily considered the comparison between TB patients and healthy controls or TB patients before and after treatment. Although transcriptomic profiling demonstrates that even signatures derived purely from such designs can be used to reliably discriminate between TB and other diseases with similar symptoms, 13 the inclusion of patients with other diseases in the study design of metabolic, epigenetic, and proteomic profiling is a necessary next step.
Outlook
High-throughput techniques such as transcriptomics have demonstrated their ability to not only distinguish TB patients from healthy individuals, but also to discriminate between TB and other diseases, monitoring treatment outcome and even predicting the onset of active TB months before a clinical diagnosis can be performed. Although current biosignatures are composed of dozens, if not hundreds of variables, first attempts to reduce the number of transcripts in transcriptomic profiling of TB show that not only is the information contained in such large biosignatures redundant, but that more specific signatures can be derived by a more selective approach. 13 Biomarkers in TB are by no means limited to the transcriptome, and several studies have shown that TB manifests itself on different levels. Given that even within blood, transcriptomic profiles (derived only from peripheral blood cells) are not necessarily fully correlated to profiles of serum molecules (derived from other cells as well as peripheral blood cells), combining biomarkers from these different platforms may improve the overall performance of biosignatures.
Most importantly, new, independent studies in different cohorts are needed to allow for meta-analyses and the construction of concise, universal, and predictive TB biosignatures.
